Amgen's Murdo Gordon On Generating Sales Growth In A Challenging Commercial Year

Newer products are gaining ground, but not fast enough to replace sales as blockbuster products face competition. Scrip spoke with the company's global commercial head about the strategy going forward.

Murdo_Gordon_1200.jpg
Amgen Commercial Chief Murdo Gordon

Amgen Inc. is at a crossroads as sales of multiple legacy products face generics, biosimilars and other competitors, while new revenue generators haven't grown enough to fill blockbuster sales gaps. Executive vice president of global commercial operations Murdo Gordon joined the company last year and is tasked with keeping Repatha, Aimovig and Evenity on the path to growth, while preventing sales of Neulasta, Enbrel and Sensipar from traveling too far south.

Gordon is likely to face the bulk of analysts' questions during the company's 30 July call to discuss second quarter...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.